Cambridge-based Raze Therapeutics announced its launch Monday, adding that it has closed on a $24 million Series A financing.
Investors in the Series A financing include Atlas Venture, MPM Capital Management, MS Ventures, Partners Innovation Fund, Astellas Venture Management, and Novartis, the Raze press release said.
Atlas partner Jason Rhodes is Raze’s acting chief executive.
Read more at BostonGlobe.com... Discuss